Secukinumab

BOSTON — Quality of life improvements were recorded in most pediatric patients with psoriasis who received secukinumab, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Secukinumab provides early, clinically meaningful, statistically significant and sustained improvements in patient-reported outcomes across all doses, compared with placebo, in active psoriatic arthritis, according to data.

Withdrawal and reinitiation of treatment with most biologic agents had minimal impact on efficacy in plaque psoriasis, according to a study.

Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis, resulting in a significantly longer time to flare versus placebo, according to data presented at ACR Convergence 2021.

Secukinumab improves non-radiographic axial spondyloarthritis signs and symptoms across patients grouped by C-reactive protein level, MRI score, HLA-B27 status and sex, according to data published in Arthritis Research & Therapy.

Secukinumab 300 mg administered with an auto-injector pen showed significant efficacy and tolerability compared with placebo, according to clinical trial results presented at the EADV Congress virtual meeting.

Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

The AMA has adopted a new policy that discourages health insurance companies from offering financial incentives to patients for switching medications, according to the organization.

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at the EULAR 2021 Congress.

Secukinumab is effective in psoriatic arthritis at 6 and 12 months, with significantly better remission, low disease activity, retention and response rates in patients naïve to disease-modifying antirheumatic drugs, according to data.